Focus on Anticoagulation Care

Back to articles

New oral option for cancer-associated VTE

KEY POINT

Use of long-term oral edoxaban (Savaysa—Daiichi-Sankyo) in patients with cancer and an acute venous thromboembolism (VTE) was found to be noninferior to long-term use of subcutaneous dalteparin for recurrent VTE or major bleeding, according to results of the Hokusai VTE Cancer trial published in the New England Journal of Medicine.

SOURCES

Raskob GE, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–24.

Hirsh J, et al. Edoxaban for the treatment of venous thromboembolism in patients with cancer. N Engl J Med. 2018;378(7):673–4.